Hologic, Inc. (HOLX)

76,71 -0,48 (-0,62%) Börsenschluss: 04:00PM EDT

Hologic, Inc.

250 Campus Drive
Marlborough, MA 01752
United States
508 263 2900
https://www.hologic.com

Sektor(en): Healthcare
Branche: Medical Instruments & Supplies
Vollzeitmitarbeiter: 6.990

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Stephen P. MacMillan	Chairman, CEO & President	4,12M	4,73M	1964
Ms. Karleen M. Oberton	Chief Financial Officer	1,6M	490,44k	1971
Mr. Essex D. Mitchell	Chief Operating Officer	925,29k	N/A	1980
Mr. John M. Griffin	General Counsel	1,47M	948,95k	1961
Mr. Jan Verstreken	Group President of International	1,44M	N/A	1968
Mr. Paul Malenchini	Chief Information Officer	N/A	N/A	N/A
Ryan M. Simon	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Peter P. Dunne	Senior Vice President of Human Resources	N/A	N/A	1956
Ms. Monica Aguirre Berthelot	VP & Chief of Staff	N/A	N/A	N/A
Mr. Erik S. Anderson	Division President of Breast & Skeletal Health Solutions	N/A	N/A	1982

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Corporate Governance

Hologic, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 7. Die grundlegenden Scores sind Audit: 7, Vorstand: 7, Shareholderrechte: 7, Kompensation: 6.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.